Premium
Unraveling the Role of Arg4 and Arg6 in the Auto‐Inhibition Mechanism of GSK 3 β From Molecular Dynamics Simulation
Author(s) -
Mou Linkai,
Li Molin,
Lu ShaoYong,
Li Shuai,
Shen Qiancheng,
Zhang Jian,
Li Chuangang,
Lu Xuefeng
Publication year - 2014
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12286
Subject(s) - gsk 3 , wnt signaling pathway , phosphorylation , molecular dynamics , glycogen synthase , serine , chemistry , kinase , protein kinase b , mutant , threonine , signal transduction , gsk3b , biochemistry , wild type , biology , biophysics , computational chemistry , gene
Glycogen synthase kinase 3 β ( GSK 3 β ) is a multifunctional serine/threonine protein kinase that is involved in several biological processes including insulin and Wnt signaling pathways. GSK 3 β can be phosphorylated by the protein kinase B ( PKB ). The mutations of A rg4 and A rg6 to alanine at N ‐terminal GSK 3 β have been reported to impair its ability to autophosphorylate at S er9. Despite the extensive experimental observations, the detailed mechanism for the auto‐inhibition of GSK 3 β has not been rationalized at the molecular level. In this study, we have demonstrated the structural consequences of GSK 3 β R 4 A and R 6 A mutations and the atomic changes that influenced the loss of PKB ‐binding affinity. Molecular dynamics simulation results suggested significant loss in atomic contacts in the R 4 A and R 6 A mutant systems compared to the wild‐type system. Furthermore, we observed many notable changes (such as conformation, residues motions, hydrogen bonds, and binding free energy) in the mutated GSK 3 β – PKB complexes. Loss of binding affinity in the mutated systems rendered the decrease in GSK 3 β phosphorylation, which, in turn, impaired the auto‐inhibition of GSK 3 β . The significant outcomes obtained from this study can explain the auto‐inhibition of GSK 3 β and maybe facilitate type 2 diabetes mellitus researches and in developing the potent drug therapies.